Earnings ·
AbbVie reports Q3 diluted EPS of $2.37 and raises full-year guidance to $13.95-$13.99
ABBVAbbVie Inc.
AbbVie Inc. reported third-quarter 2026 financial results, posting GAAP diluted earnings per share of $2.37 and adjusted diluted EPS of $3.82. Net revenues reached $17.4 billion, a 10.5 percent increase on an operational basis, driven by strong growth in the immunology portfolio where Skyrizi generated $5.78 billion. The company raised its full-year 2026 adjusted diluted EPS guidance range to $13.95-$13.99 from $13.76-$13.96 and announced a 5.2 percent increase in its quarterly dividend to $1.82 per share, payable February 16, 2027. AbbVie is a pharmaceutical company focused on immunology, neuroscience, oncology, and aesthetics.